Journal
CANCER IMMUNOLOGY RESEARCH
Volume 8, Issue 9, Pages 1180-1192Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-19-0826
Keywords
-
Categories
Funding
- University of Lausanne
- Swiss Cancer League [3679-08-2015, 4840-08-2019, 3971-082016]
- Max Cloetta Foundation
- Swiss National Foundation [310030_182680]
- Cancer Research Institute, Ludwig Cancer Research
- Roche
- Swiss National Science Foundation (SNF) [310030_182680] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Bladder cancer is one of the most common malignancies and has poor prognosis for patients with locally advanced, muscle-invasive, disease despite the efficacy of immune checkpoint blockade. To develop more effective immunotherapy strategies, we studied a genetic mouse model carrying deletion of Tp53 and Pten in the bladder, which recapitulates bladder cancer tumorigenesis and gene expression patterns found in patients. We discovered that tumor cells became more malignant and the tumor immune microenvironment evolved from an inflammatory to an immunosuppressive state. Accordingly, treatment with anti-PD1 was ineffective, but resistance to anti-PD1 therapy was overcome by combination with a CD40 agonist (anti-CD40), leading to strong anti-tumor immune responses. Mechanistically, this combination led to CD8(+) T-cell recruitment from draining lymph nodes. CD8(+) T cells induced an IFN gamma-dependent repolarization toward M1-like/IFN beta-producing macrophages. CD8(+) T cells, macrophages, IFN I, and IFN II were all necessary for tumor control, as demonstrated in vivo by the administration of blocking anti-bodies. Our results identify essential cross-talk between innate and adaptive immunity to control tumor development in a model representative of anti-PD1-resistant human bladder cancer and provide scientific rationale to target CD40 in combination with blocking antibodies, such as anti-PD1/PD-L1, for muscle-invasive bladder cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available